Aβ-Amyloid deposition in patients with parkinson disease at risk for development of dementia

Neurology

Volumn 79, Issue 11, 2012, Pages 1161-1167

  Petrou, Myria ^a,c   Bohnen, Nicolaas I ^a,b,d   Müller, Martijn L T M ^a   Koeppe, Robert A ^a   Albin, Roger L ^b,d   Frey, Kirk A ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; PITTSBURGH COMPOUND B; VESICULAR MONOAMINE TRANSPORTER 2;

ARTICLE; ATTENTION; BRAIN LEVEL; BRAIN REGION; CLINICAL ARTICLE; COGNITION; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DEMENTIA; EXECUTIVE FUNCTION; HUMAN; MEMORY; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NEUROPSYCHOLOGY; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RATING SCALE; WECHSLER ADULT INTELLIGENCE SCALE SCORE;

EID: 84867510729     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182698d4a     Document Type: Article

References (40)

1. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007;22:1689-1707; quiz 1837.
2. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh- Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: An 8-year prospective study. Arch Neurol 2003;60:387-392.
3. Aarsland D, Perry R, Brown A, Larsen JP, Ballard C. Neuropathology of dementia in Parkinson's disease: A prospective, community-based study. Ann Neurol 2005;58:773-776.
4. Hurtig HI, Trojanowski JQ, Galvin J, et al. Alphasynuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 2000;54:1916-1921.
5. Braak H, Rub U, Jansen Steur EN, Del Tredici K, de Vos RA. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 2005;64:1404-1410.
6. Ballard C, Ziabreva I, Perry R, et al. Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology 2006;67:1931-1934.
7. Sabbagh MN, Adler CH, Lahti TJ, et al. Parkinson disease with dementia: Comparing patients with and without Alzheimer pathology. Alzheimer Dis Assoc Disord 2009;23: 295-297.
8. Compta Y, Parkkinen L, O'Sullivan SS, et al. Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? Brain 2011;134:1493-1505.
9. Klunk WE, Engler E, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease using the novel positron emission tomography tracer, Pittsburgh compound-B. Ann Neurol 2004;55:306-319.
10. Foster ER, Campbell MC, Burack MA, et al. Amyloid imaging of Lewy body-associated disorders. Mov Disord 2010;25:2516-2523.
11. Villemagne VL, Ong K, Mulligan RS, et al. Amyloid imaging with 18F-florbetaben in Alzheimer disease and other dementias. J Nucl Med 2011;52:1210-1217.
12. Maetzler W, Reimold M, Liepelt I, et al. [11C]PIB binding in Parkinson's disease dementia. Neuroimage 2008;39: 1027-1033.
13. Edison P, Rowe CC, Rinne JO, et al. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 2008;79:1331-1338.
14. Gomperts SN, Rentz DM, Moran E, et al. Imaging amyloid deposition in Lewy body diseases. Neurology 2008; 71:903-910.
15. Janvin CC, Larsen JP, Aarsland D, Hugdahl K. Subtypes of mild cognitive impairment in Parkinson's disease: Progression to dementia. Mov Disord 2006;21:1343-1349.
16. Caviness JN, Driver-Dunckley E, Connor DJ, et al. Defining mild cognitive impairment in Parkinson's disease. Mov Disord 2007;22:1272-1277.
17. Hughes TA, Ross HF, Musa S, et al. A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease. Neurology 2000;54:1596-1602.
18. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
19. Hoehn MM, Yahr MD. Parkinsonism: Onset, progression and mortality. Neurology 1967;17:427-442.
20. Delis DC, Kramer JH, Kaplan E, Ober BA. California Verbal Learning Test Manual, Adult Version, 2nd ed. San Antonio, TX: The Psychological Corporation; 2000.
21. Wechsler D. WAIS III Technical Manual. San Antonio, TX: The Psychological Corporation; 1997.
22. Delis DC, Kaplan E, Kramer JH, eds. Delis-Kaplan Executive Function System (D-KEFS): Examiner's Manual. San Antonio, TX: The Psychological Corporation; 2001.
23. Stroop Jr. Studies of interference in serial verbal reactions. J Exp Psychol 1935;18:643-662.
24. Bohnen N, Jolles J, Twijnstra A. Modification of the Stroop Color Word Test improves differentiation between patients with mild head injury and matched controls. Clin Neuropsychol 1992;6:178-184.
25. Benton AL, Varney NR, Hamsher K. Judgment of Line Orientation, Form V. Iowa City: University of Iowa Hospitals; 1975.
26. Koeppe RA, Frey KA. Equilibrium analysis of [11C]PIB studies. Neuroimage 2008;41:T30.
27. Jewett DM, Kilbourn MR, Lee LC. A simple synthesis of [11C]dihydrotetrabenazine (DTBZ). Nucl Med Biol 1997; 24:197-199.
28. Koeppe RA, Frey KA, Kume A, Albin R, Kilbourn MR, Kuhl DE. Equilibrium versus compartmental analysis for assessment of the vesicular monoamine transporter using -[11C]dihydrotetrabenazine (DTBZ) and positron emission tomography. J Cereb Blood Flow Metab 1997; 17:919-931.
29. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996;16:834-840.
30. Koeppe RA, Frey KA, Kuhl DE, Kilbourn MR. Assessment of extrastriatal vesicular monoamine transporter binding site density using stereoisomers of [11C]dihydrotetrabenazine. J Cereb Blood Flow Metab 1999;19:1376-1384.
31. Burke JF, Albin RL, Koeppe RA, et al. Assessment of mild dementia with amyloid and dopamine terminal positron emission tomography. Brain 2011;134:1647-1657.
32. Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease. Neurology 2006;67:446-452.
33. Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010;31: 1275-1283.
34. Frey KA, Koeppe RA. Surface projection maps of cortical amyloid binding reveal canonical patterns in neurodegenerative dementias. J Nucl Med 2012(suppl 1):144. Abstract.
35. Bohnen NI, Albin RL, Koeppe RA, et al. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab 2006;26:1198-1212.
36. Johansson A, Savitcheva I, Forsberg A, et al. [11C]-PIB imaging in patients with Parkinson's disease: Preliminary results. Parkinsonism Relat Disord 2008;14:345-347.
37. Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK. Striatal beta-amyloid deposition in Parkinson disease with dementia. J Neuropathol Exp Neurol 2008;67:155-161.
38. Kalaitzakis ME, Pearce RK, Gentleman SM. Clinical correlates of pathology in the claustrum in Parkinson's disease and dementia with Lewy bodies. Neurosci Lett 2009;461: 12-15.
39. Montine TJ, Shi M, Quinn JF, et al. CSF A42 and tau in Parkinson's disease with cognitive impairment. Mov Disord 2010;25:2682-2685.
40. Leverenz JB, Watson GS, Shofer J, Zabetian CP, Zhang J, Montine TJ. Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson's disease. Parkinsonism Relat Disord 2011;17:61-64.